Aller au contenu
Varieties from the European CatalogueGrown in FranceSlow dryingSame-day dispatch — before noonEU delivery — 24-72 hRight of withdrawal — 14 daysCertificate available — per batch

← Journal/11 August 2026·5 min de lecture

Is CBD a drug? What the law and science say

Par ·

No, in the legal sense of the word: cannabidiol appears on no list of narcotics in France, and the Court of Justice of the European Union ruled in 2020 that it could not be treated as one. In the pharmacological sense, CBD is a psychoactive substance in the broad sense (it acts on the nervous system) but not a psychotropic one: it produces no intoxication, and the World Health Organization has identified neither abuse potential nor risk of dependence. The confusion comes from the plant of origin, hemp, and from the THC that can accompany it. Let us untangle the three questions the word "drug" covers.

Is CBD a drug? What the law and science say

Question 1: is CBD a narcotic?

This is the legal question, and the answer is settled. In France, narcotics are the substances entered on lists fixed by ministerial order; cannabidiol does not appear on them. The applicable framework, the decree of 30 December 2021, expressly authorises the extraction and use of CBD from hemp varieties whose Δ⁹-THC does not exceed 0.30%, a threshold whose agronomic and regulatory origin we have traced.

This framework is not an administrative tolerance: it is the consequence of a European court decision. In the Kanavape ruling of 19 November 2020 (case C-663/18), the Court of Justice of the European Union held that a member state cannot ban the marketing of CBD lawfully produced in another member state, precisely because "the CBD at issue cannot be regarded as a narcotic drug" within the meaning of the international conventions.

Question 2: does CBD cause dependence?

This is the health question, and it has been formally examined. The Expert Committee on Drug Dependence of the World Health Organization devoted to cannabidiol a critical review published in 2018, whose conclusions fit in two sentences: CBD in its pure state exhibits no abuse potential, and no public health problem has been associated with its use. On that basis, the WHO recommended not scheduling it under the international drug conventions.

That does not make CBD a harmless substance: adverse effects exist (drowsiness, digestive troubles, drug interactions) and we have devoted a full article to them. But the absence of any documented dependence syndrome clearly sets it apart from the substances the word "drug" designates in everyday language.

Question 3: does CBD get you high?

This is the question of lived experience, and it rests on a precise distinction. Psychoactive means acting on the central nervous system: coffee is, and so is CBD, since it modulates, among other things, serotonin and anandamide signalling. Psychotropic, in the everyday sense of altered perception and behaviour, describes cannabis intoxication: it is produced by THC, a direct agonist of the CB1 receptors, which CBD is not.

Concretely, CBD alters neither the perception of time, nor coordination, nor judgement. Our article dedicated to this question details the mechanisms; the nuance that remains concerns full-spectrum products, which contain residual THC below the legal threshold, in a quantity insufficient for intoxication but detectable by a sensitive test, as the drug-testing guide explains.

Why the confusion persists

Three reasons sustain the conflation. The first is botanical: CBD and THC come from the same plant, and a hemp flower looks like a narcotic cannabis flower, to the point that law enforcement itself resorts to analysis to tell them apart. The second is regulatory: the status of CBD long remained unclear in France, and it took the 2020 ruling and then the 2021 decree to stabilise it. The third is commercial: part of the market deliberately keeps up the visual codes of recreational cannabis, which feeds suspicion of the entire sector.

Our position is constant: the way out of ambiguity is the published analysis. A product whose certificate details the cannabinoids, batch by batch, has nothing to hide about its nature.

Frequently asked questions

Is CBD legal in France in 2026?

Yes. The framework is set by the decree of 30 December 2021: products from hemp varieties whose Δ⁹-THC does not exceed 0.30%, with no therapeutic claims and outside the narcotics regime. Sale is unrestricted to adults.

Is CBD a drug in the eyes of the law?

No. It appears on no list of narcotics, and the Court of Justice of the European Union explicitly ruled in 2020 that it could not be considered a narcotic within the meaning of the international conventions.

Can you become dependent on CBD?

No abuse potential or dependence syndrome was identified by the WHO's critical review in 2018. Adverse effects do exist, however, notably interactions with certain medicines, which justify medical advice for anyone on treatment.

Can CBD make a drug test positive?

CBD itself is not what the tests look for. A full-spectrum product nonetheless contains residual THC below the legal threshold, which sustained consumption can make detectable: a real point of vigilance for drivers.


Written by the Phytogrammes team

Every article in this journal draws on primary sources (ANSM, EFSA, EUR-Lex, peer-reviewed publications) and on the lab's own practice: batch-by-batch HPLC analyses, measured cannabinoid profiles. Our approach.

Article published on . CBD is not a medicine.

Phytogrammes products that pair well